Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Amgen |
---|---|
Information provided by: | Amgen |
ClinicalTrials.gov Identifier: | NCT00630786 |
This is an exploratory phase 1b/2, global, multicenter, single-arm, 2-part (phase 1b and 2) study of AMG 655 in combination with panitumumab in subjects with Metastatic Colorectal Cancer.
The objective for Part 1 is to identify a tolerable dose of AMG 655 in combination with panitumumab based on the incidence of dose-limiting toxicities in subjects with Metastatic Colorectal Cancer.
The objective for Part 2 is to evaluate the objective response rate stratified by KRAS status (wild-type versus mutant) in subjects with Metastatic Colorectal Cancer treated with the combination of panitumumab and AMG 655 (tolerable dose identified in part 1).
Condition | Intervention | Phase |
---|---|---|
Colon Cancer Colorectal Cancer Rectal Cancer Metastatic Colorectal Cancer Oncology |
Drug: Panitumumab in combination with AMG 655 |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase 1b/2 Trial of AMG 655 in Combination With Panitumumab in Subjects With Metastatic Colorectal Cancer |
Estimated Enrollment: | 65 |
Study Start Date: | January 2008 |
Estimated Study Completion Date: | January 2010 |
Estimated Primary Completion Date: | November 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Single: Experimental |
Drug: Panitumumab in combination with AMG 655
Part 1. A tolerable dose level of AMG 655 [up to 3 dose levels of AMG 655 (10 mg/kg, 3 mg/kg, or 1 mg/kg) will be evaluated in de-escalation manner] in combination with panitumumab 6 mg/kg. Part 2. If and when a tolerable dose level of AMG 655 in combination with panitumumab is identified, then enrollment into part 2 will be opened. Subjects enrolled in part 2 will be treated with the combination that is determined tolerable in part 1. |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
101 Histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum 102 Radiographically documented disease progression per modified RECIST during or following treatment with fluoropyrimidine, irinotecan, and/or oxaliplatin chemotherapy for Metastatic Colorectal Cancer. Progressive disease must be documented during or ≤ 6 months after the last dose of the most recent chemotherapy regimen prior to enrollment.
103 At least 1 uni-dimensionally measurable lesion measuring ≥ 20 mm in one dimension per modified RECIST. Lesion must not be chosen from a previously irradiated field, unless there has been documented disease progression in that field after irradiation and prior to enrollment. All sites of disease must be evaluated.
104 Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 105 Available archived paraffin-embedded tumor tissue from the primary tumor or metastasis for submission to the central laboratory 106 Man or woman ≥ 18 years of age at the time of enrollment 107 Hematologic function within the following limits:
Exclusion Criteria:
201 History of other primary cancer, unless:
Other primary solid tumor curatively treated with no known active disease present and no treatment administered for ≥ 5 years before enrollment 202 Prior treatment with anti-EGFr inhibitors (eg, cetuximab, erlotinib, gefitinib), unless treatment was received in the adjuvant setting ≥ 6 months before enrollment 203 Use of systemic chemotherapy and radiotherapy ≤ 30 days before enrollment 204 Use of prior anti-tumor therapies with a short serum half-life (less than 1 week) including prior experimental agents or approved anti-tumor small molecules ≤ 30 days before enrollment 205 Use of anti-tumor therapies with a longer serum half-life (eg, bevacizumab) including prior experimental or approved protein/antibodies ≤ 42 days before enrollment 206 Any investigational agent or therapy ≤ 30 days before enrollment 207 Known allergy or hypersensitivity to any component of panitumumab and/or AMG 655 208 History of or known presence of central nervous system (CNS) metastases 209 History of interstitial lung disease (eg, pneumonitis, pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest computerized tomography (CT) scan 210 Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrollment 211 Active inflammatory bowel disease or other active bowel disease causing chronic diarrhea (defined as ≥ CTC grade 2 [CTCAE version 3.0]) 212 Known positive test for human immunodeficiency virus (HIV) infection, hepatitis C virus, acute or chronic hepatitis B infection 213 Any co-morbid disease or condition that could increase the risk of toxicity (eg, significant ascites, significant pleural effusion) 214 Any uncontrolled concurrent illness (eg, infection, bleeding) or history of any medical condition that may interfere with the interpretation of the study results 215 Major surgical procedure (requiring general anesthesia) ≤ 28 days or minor surgical procedure (excluding central venous catheter placement) ≤ 14 days before enrollment. Subjects must have recovered from surgery related toxicities.
216 Other investigational procedures are excluded 217 Subject is currently pregnant or breast feeding 218 Man or woman of childbearing potential who is not willing to use adequate contraceptive precautions during treatment and for 6 months (for women) or 1 month (for men) after the last investigational product administration. Adequate contraceptive precautions includes double barrier contraceptive methods (eg, diaphragm and condom) or abstinence.
219 Previously enrolled into this study 220 Subject unwilling or unable to comply with study requirements
United States, Florida | |
Research Site | |
Boynton Beach, Florida, United States | |
United States, New Jersey | |
Research Site | |
Denville, New Jersey, United States | |
United States, North Carolina | |
Research Site | |
Durham, North Carolina, United States | |
United States, Ohio | |
Research Site | |
Middletown, Ohio, United States | |
United States, South Carolina | |
Research Site | |
Greenville, South Carolina, United States | |
United States, Tennessee | |
Research Site | |
Nashville, Tennessee, United States | |
Research Site | |
Memphis, Tennessee, United States | |
Research Site | |
Collierville, Tennessee, United States | |
United States, Texas | |
Research Site | |
Austin, Texas, United States | |
Belgium | |
Research Site | |
Gent, Belgium | |
Research Site | |
Bruxelles, Belgium | |
France | |
Research Site | |
Boulogne Billancourt, France |
Study Director: | MD | Amgen |
Responsible Party: | Amgen Inc. ( Global Development Leader ) |
Study ID Numbers: | 20060332 |
Study First Received: | February 28, 2008 |
Last Updated: | January 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00630786 |
Health Authority: | EU: CHMP; France: Ministry of Health; Germany: Federal Institute for Drugs and Medical Devices; United States: Food and Drug Administration; United States: Institutional Review Board; United States: Western Institutional Review Board; Belgium: Federal Public Service (FPS) Health, Food Chain Safety and Environment |
Digestive System Neoplasms Rectal Neoplasms Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Intestinal Neoplasms |
Rectal neoplasm Digestive System Diseases Gastrointestinal Neoplasms Colonic Neoplasms Rectal cancer Colorectal Neoplasms |
Neoplasms Neoplasms by Site |